Message from CEO, Mr. Brent Willis, Voyageur Pharmaceuticals Ltd. (“Voyageur”)
Dear Voyageur Investor,
Having worked for over 30 years in the Barium space, one important fact stands out to me. To make a high grade (Pharmaceutical) deposit successful, a company must sell the mineral in its final form to the end user. This strategy eliminates all middlemen in the supply chain and reduces overall costs. Once this is accomplished, the company will receive the highest profit margin possible for that pharmaceutical mineral (API, active pharmaceutical ingredient). This increases the profitability of the project and increases the asset value of the mine. By creating our own 100% fully integrated supply chain, we insulate our company from geopolitical risks and lower our over all supply chain costs. This is the key aspect every investor looks for in a great company. Our motto “From The Earth To The Bottle”, fully encompasses this strategy. This is the strategy that created Voyageur Pharmaceuticals.
Voyageur has taken the steps to realize the highest margin possible on our Frances Creek barium sulfate deposit. Selling the Frances Creek barium sulfate into the pharmaceutical industry – directly to the end user – will create substantial cash flow, based on a small mine production. When we started down the road of entering the pharmaceutical industry, we where presented with a few major challenges. One of the challenges, at our early stage, was how to finance and build an expensive Health Canada/FDA/GMP (Good Manufacturing Practices) approved pharmaceutical plant? This is significant. These plants are highly regulated and require investments in the ten’s of millions of dollars – and often much more.
We resolved this problem by finding a Calgary based manufacturing partner and international drug manufacturing companies. We are utilizing third party manufacturing and third party mineral ingredients to kick start our cash flow and solidify our feasibility of our projects. Once we are cash flowing we will develop our mineral resources and secure the financing necessary to build a large GMP pharmaceutical production facility. This facility will be built so we can scale up to take over the majority of the market share available, over time. By having the lowest cost ingredients in this space, we are poised to implement a significant growth strategy over the coming years.
We are entering a US$7,000,000,000 global radio-graphic industry. Because we own the only natural pharmaceutical grade barium sulfate project out side of China, we have the ability to create high growth in this sector. Currently our competition use barium contrast as leverage in order to secure iodine contrast sales. Once we begin our fully integrated sales strategy, by owning our own ingredients, we believe we can make a rapid penetrating thrust into these markets.
In addition to marketing our generic drugs, we will also begin to develop new drugs and create a pipeline of exciting new products. We are currently moving forward with our due diligence on other potentially exciting drugs to add to our development program.
I hope investors will join us on our road to growth and prosperity. Our vision is to build a billion dollar company and we have begun to take the steps to accomplish our goals. We continue to move our company forward towards a very bright and profitable future. I hope everyone looks at the challenges we have overcome and the milestones we are about to reach.